Researchers have developed a novel method using CRISPR to study transcription factors affecting blood cell development. The ...

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to this ...

Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 ...

Nurix stock gains as SNY expands its partnership, licensing a research program targeting a previously untreatable transcription factor for autoimmune diseases.

What's been going on in the life sciences world? Check out Week in Brief for an overview of the biggest news from the last ...

Transcription factor networks disproportionately enrich for heritability of blood cell phenotypesPublication: ...

Sarcomas are among the rarest and most enigmatic forms of cancer, accounting for just 1% of all adult cancer diagnoses ...

Stock analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a ...

US clinical-stage biotech Nurix Therapeutics (Nasdaq: NRIX) announced that Sanofi (Euronext: SAN) has exclusively licensed an ...